RNS Number : 9840J
Omega Diagnostics Group PLC
22 August 2023
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega", the "Company" or the "Group")

 

Directorate Change

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that Chris Lea, Group Finance Director of the Company, will be stepping down as a Director and leaving the Company with immediate effect.

 

Chris has been instrumental in selling the Alva site and subsequent sale of the CD4 Business along with a restructuring of Omega, based in Ely, Cambridgeshire. The restructuring and disposals were key in refocusing the Company on food intolerance testing and ensuring it has sufficient resources to drive Omega forward. Chris is based in Scotland and his stepping down is in line with the Company strategy to focus more of its resources in and around the Company's headquarters in Ely, Cambridge.

 

As per the recent results, the Company remains very well-funded with £5.1m of cash at 31 March 2023. This is more than sufficient to build on the platform Omega has to drive a profitable and sustainable Company.

 

Omega intends to change its name to Cambridge Nutritional Sciences at the upcoming Annual General Meeting and intends to appoint an interim CFO shortly.

 

Simon Douglas, Chairman of Omega, said: "We thank Chris for all his efforts and fully appreciate how instrumental he was in the refocusing and restructuring of the Company. We wish him all the best for the future."

 

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR





finnCap Ltd 

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Nigel Birks/Harriet Ward (ECM)






Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 85 countries and is now focused on the health and nutrition sector.www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUPWRUPWGQG